These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Association of MAPT Subhaplotypes With Risk of Progressive Supranuclear Palsy and Severity of Tau Pathology. Heckman MG; Brennan RR; Labbé C; Soto AI; Koga S; DeTure MA; Murray ME; Petersen RC; Boeve BF; van Gerpen JA; Uitti RJ; Wszolek ZK; Rademakers R; Dickson DW; Ross OA JAMA Neurol; 2019 Jun; 76(6):710-717. PubMed ID: 30882841 [TBL] [Abstract][Full Text] [Related]
9. Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy. Brown RG; Lacomblez L; Landwehrmeyer BG; Bak T; Uttner I; Dubois B; Agid Y; Ludolph A; Bensimon G; Payan C; Leigh NP; Brain; 2010 Aug; 133(Pt 8):2382-93. PubMed ID: 20576697 [TBL] [Abstract][Full Text] [Related]
10. The tau gene A0 polymorphism in progressive supranuclear palsy and related neurodegenerative diseases. Morris HR; Janssen JC; Bandmann O; Daniel SE; Rossor MN; Lees AJ; Wood NW J Neurol Neurosurg Psychiatry; 1999 May; 66(5):665-7. PubMed ID: 10209184 [TBL] [Abstract][Full Text] [Related]
11. 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy. Passamonti L; Vázquez Rodríguez P; Hong YT; Allinson KS; Williamson D; Borchert RJ; Sami S; Cope TE; Bevan-Jones WR; Jones PS; Arnold R; Surendranathan A; Mak E; Su L; Fryer TD; Aigbirhio FI; O'Brien JT; Rowe JB Brain; 2017 Mar; 140(3):781-791. PubMed ID: 28122879 [TBL] [Abstract][Full Text] [Related]
12. Different MAPT haplotypes are associated with Parkinson's disease and progressive supranuclear palsy. Ezquerra M; Pastor P; Gaig C; Vidal-Taboada JM; Cruchaga C; Muñoz E; Martí MJ; Valldeoriola F; Aguilar M; Calopa M; Hernandez-Vara J; Tolosa E Neurobiol Aging; 2011 Mar; 32(3):547.e11-6. PubMed ID: 19879020 [TBL] [Abstract][Full Text] [Related]
13. Effect of ApoE and tau on age of onset of progressive supranuclear palsy and multiple system atrophy. Morris HR; Schrag A; Nath U; Burn D; Quinn NP; Daniel S; Wood NW; Lees AJ Neurosci Lett; 2001 Oct; 312(2):118-20. PubMed ID: 11595348 [TBL] [Abstract][Full Text] [Related]
15. An R5L tau mutation in a subject with a progressive supranuclear palsy phenotype. Poorkaj P; Muma NA; Zhukareva V; Cochran EJ; Shannon KM; Hurtig H; Koller WC; Bird TD; Trojanowski JQ; Lee VM; Schellenberg GD Ann Neurol; 2002 Oct; 52(4):511-6. PubMed ID: 12325083 [TBL] [Abstract][Full Text] [Related]
16. Genetics of Progressive Supranuclear Palsy: A Review. Wen Y; Zhou Y; Jiao B; Shen L J Parkinsons Dis; 2021; 11(1):93-105. PubMed ID: 33104043 [TBL] [Abstract][Full Text] [Related]
17. Clinical and cognitive correlations of regional gray matter atrophy in progressive supranuclear palsy. Giordano A; Tessitore A; Corbo D; Cirillo G; de Micco R; Russo A; Liguori S; Cirillo M; Esposito F; Tedeschi G Parkinsonism Relat Disord; 2013 Jun; 19(6):590-4. PubMed ID: 23477861 [TBL] [Abstract][Full Text] [Related]
18. Regional expression of the MAPT gene is associated with loss of hubs in brain networks and cognitive impairment in Parkinson disease and progressive supranuclear palsy. Rittman T; Rubinov M; Vértes PE; Patel AX; Ginestet CE; Ghosh BCP; Barker RA; Spillantini MG; Bullmore ET; Rowe JB Neurobiol Aging; 2016 Dec; 48():153-160. PubMed ID: 27697694 [TBL] [Abstract][Full Text] [Related]
19. Genetic bases of Progressive Supranuclear Palsy: the MAPT tau disease. Borroni B; Agosti C; Magnani E; Di Luca M; Padovani A Curr Med Chem; 2011; 18(17):2655-60. PubMed ID: 21568901 [TBL] [Abstract][Full Text] [Related]